CME Group, S&P Group Agree to Sell OSTTRA to KKR in $3.1 Billion Deal
CME Group and S&P Global have agreed to sell OSTTRA to investment funds managed by investment firm KKR for an enterprise value of $3.1 billion.
CME Group (CME): Strong Industry, Solid Earnings Estimate Revisions
CME Group (CME) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CME Gains 11% YTD: Time to Buy the Stock at a P/E of 23.82X?
Let us delve deeper to find out what to do with CME Group stock now.
Will CME (CME) Beat Estimates Again in Its Next Earnings Report?
CME (CME) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CME Group: A Fortress in Financial Infrastructure
Explore the exciting world of CME Group (CME 0.17%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
CME Group: A High-Yield Tollbooth On Global Financial Volatility
CME Group is a high-margin, capital-light business benefiting from network effects, offering strong cash flow and a competitive dividend yield, making it attractive for income investors. CME's wide moat is reinforced by its dominance in U.S. interest rate futures and exclusive product licenses, ensuring durable competitive advantages. The company's scalable business model and consistent dividend policy, including a variable annual dividend, provide potential for double-digit annual returns.
Are You Looking for a Top Momentum Pick? Why CME Group (CME) is a Great Choice
Does CME Group (CME) have what it takes to be a top stock pick for momentum investors? Let's find out.
CME Group At A New All-Time High - Valuation Concerns Justified?
CME shares have delivered market-beating returns over the past two years, prompting the question of whether it's time to lock in profits. In this update, I discuss whether the rally appears sustainable against the backdrop of the 2024 results published in mid-February. The analysis focuses on average contract volumes and rates, signs of potential underinvestment given the surprisingly strong free cash flow, and includes an update on debt and leverage.
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
CME Stock: How To Use A Bull Put Spread On This Thriving Company
CME stock is thriving and reaching new highs, but here's how to cut risk when investing in the trading marketplace provider. The post CME Stock: How To Use A Bull Put Spread On This Thriving Company appeared first on Investor's Business Daily.
Markets Attempt to Rebound from Correction: Here's What to Do
Fears are lingering in a sign that market participants remain concerned about tariffs and broader economic weakness.
CME (CME) Up 3.9% Since Last Earnings Report: Can It Continue?
CME (CME) reported earnings 30 days ago. What's next for the stock?
